(Reuters) - The stock is "down on concerns that the federal circuit may invalidate the Altace patent, which would allow generics to come to the market approximately a year earlier than expected," Cowen and Co. analyst Ian Sanderson said.
King shares were off $1.84, or 8.7 percent, at $19.24 in afternoon trading on the New York Stock Exchange.
Read more at Reuters.com Hot Stocks News
King shares were off $1.84, or 8.7 percent, at $19.24 in afternoon trading on the New York Stock Exchange.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment